Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 16/20 | 0.71 |
| ▸ | ADORA2A | P29274 | 14/20 | 0.71 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.71 |
| ▸ | GRM5 | P41594 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26632952 | 1.00 | ADORA1 (0.71) | ADORA1ADORA2AADORA2BGRM5HSD17B10 | |
| SCHEMBL26632974 | 0.91 | ADORA1 (0.59) | ADORA1ADORA2AADORA2BGRM5HSD17B10 | |
| SCHEMBL30656203 | 0.91 | ADORA1 (0.59) | ADORA1ADORA2AADORA2BGRM5HSD17B10 | |
| SCHEMBL26632983 | 0.87 | ADORA1 (0.54) | ADORA1ADORA2AADORA2BHSD17B10KDM4E | |
| SCHEMBL30656290 | 0.87 | ADORA1 (0.54) | ADORA1ADORA2AADORA2BHSD17B10KDM4E | |
| SCHEMBL31215454 | 0.85 | ADORA1 (0.61) | ADORA1ADORA2AADORA2BHSD17B10KDM4E | |
| SCHEMBL26633005 | 0.85 | ADORA1 (0.61) | ADORA1ADORA2AADORA2BHSD17B10KDM4E | |
| SCHEMBL30656273 | 0.85 | ADORA2A (0.60) | ADORA1ADORA2AADORA2BHSD17B10KDM4E | |
| SCHEMBL26632966 | 0.85 | ADORA2A (0.60) | ADORA1ADORA2AADORA2BHSD17B10KDM4E | |
| SCHEMBL30656276 | 0.83 | ADORA1 (0.49) | ADORA1ADORA2AADORA2BHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4447962-B1 | ADENOSINE 2A RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF CANCER | UNIV GENEVE (CH) | 2025-08-20 | — | — | EP | claimed |
| US-20250115592-A1 | ADENOSINE 2A RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF CANCER | UNIVERSITE DE GENEVE (CH) | 2025-04-10 | — | — | US | claimed |
| CN-119136802-A | Adenosine 2A receptor modulators for the treatment of cancer | 瑞士日内瓦大学 | 2024-12-13 | — | — | CN | claimed |
| EP-4447962-A1 | ADENOSINE 2A RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF CANCER | UNIVERSITE DE GENEVE (CH) | 2024-10-23 | — | — | EP | claimed |
| WO-2023213761-A1 | ADENOSINE 2A RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF CANCER | UNIVERSITE DE GENEVE (CH) | 2023-11-09 | — | — | WO | claimed |
| EP-4447962-B1 | ADENOSINE 2A RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF CANCER | UNIV GENEVE (CH) | 2025-08-20 | — | — | EP | disclosed |
| US-20250115592-A1 | ADENOSINE 2A RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF CANCER | UNIVERSITE DE GENEVE (CH) | 2025-04-10 | — | — | US | disclosed |
| CN-119136802-A | Adenosine 2A receptor modulators for the treatment of cancer | 瑞士日内瓦大学 | 2024-12-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115592-A1 | ADENOSINE 2A RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF CANCER | ADORA2A, ADORA2B, ADORA1 | ADORA1 3/4885ADORA2A 1/4885ADORA2B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.